PT  - JOURNAL ARTICLE
AU  - YUKI KATAOKA
AU  - KATSUYA HIRANO
AU  - TOMOKO NARABAYASHI
AU  - SATOSHI HARA
AU  - DAICHI FUJIMOTO
AU  - TAE TANAKA
AU  - NORIYUKI EBI
AU  - KEISUKE TOMII
AU  - HIROSHIGE YOSHIOKA
TI  - Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non–small Cell Lung Cancer
DP  - 2018 Jan 01
TA  - Anticancer Research
PG  - 559--563
VI  - 38
IP  - 1
4099  - http://ar.iiarjournals.org/content/38/1/559.short
4100  - http://ar.iiarjournals.org/content/38/1/559.full
SO  - Anticancer Res2018 Jan 01; 38
AB  - Aim: To find new predictive factors for the efficient use of immune checkpoint inhibitors in patients with non-small-cell lung cancer (NSCLC). Patients and Methods: In this multicenter retrospective cohort study, we evaluated consecutive patients treated with nivolumab between January and October 2016 after second-line systemic chemotherapy. The endpoint was progression-free survival (PFS), as defined by Response Evaluation Criteria in Solid Tumors version 1.1. Results: A total of 189 patients were included in the study. Sixty-four percent had received two or more prior systemic therapies. In Cox proportional hazard analyses, Eastern Cooperative Oncology Group Performance Status of 2 or more, lactate dehydrogenase (LDH) ≥217 mg/dl, and carcinoembryonic antigen ≥13.8 ng/ml were independently associated with inferior PFS. LDH was not associated in the sensitivity analysis. Conclusion: In patients with NSCLC treated with nivolumab, worse pretreatment performance status, and higher carcinoembryonic antigen were associated with inferior PFS.